Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?

L Benhaim, F Loupakis, M J Labonte, H J Lenz, Melissa LaBonte Wilson

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

For physicians facing patients with organ-limited metastases from colorectal cancer, tumor shrinkage and sterilization of micrometastatic disease is the main goal, giving the opportunity for secondary surgical resection. At the same time, for the majority of patients who will not achieve a sufficient tumor response, disease control remains the predominant objective. Since FOLFOX or FOLFIRI have similar efficacies, the challenge is to define which could be the most effective targeted agent (anti-EGFR or anti-VEGF) to reach these goals. Therefore, a priori molecular identification of patients that could benefit from anti-EGFR or anti-VEGF monoclonal antibodies (i.e. the currently approved targeted therapies for metastatic colorectal cancer) is of critical importance. In this setting, the KRAS mutation status was the first identified predictive marker of response to anti-EGFR therapy. Since it has been demonstrated that tumors with KRAS mutation do not respond to anti-EGFR therapy, KRAS status must be determined prior to treatment. Thus, for KRAS wild-type patients, the choices that remain are either anti-VEGF or anti-EGFR. In this review, we present the most updated data from translational research programs dealing with the identification of biomarkers for response to targeted therapies.

Original languageEnglish
Pages (from-to)528-35
Number of pages8
JournalJournal of hepato-biliary-pancreatic sciences
Volume19
Issue number5
DOIs
Publication statusPublished - Sep 2012

Keywords

  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Humans
  • Liver Neoplasms
  • Molecular Targeted Therapy
  • Proto-Oncogene Proteins
  • Receptor, Epidermal Growth Factor
  • Tumor Markers, Biological
  • Vascular Endothelial Growth Factor A
  • ras Proteins

Fingerprint Dive into the research topics of 'Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?'. Together they form a unique fingerprint.

Cite this